- Home
- EPAM vs ACLX Comparison
EPAM vs ACLX Comparison
Compare EPAM & ACLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EPAM | ACLX |
|---|---|---|
| Founded | 1993 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.0B | 6.7B |
| IPO Year | 2011 | 2022 |
Fundamental Metrics
Financial Performance| Metric | EPAM | ACLX |
|---|---|---|
| Price | $103.06 | $115.08 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 14 | 15 |
| Target Price | ★ $196.21 | $118.17 |
| AVG Volume (30 Days) | 1.8M | ★ 5.0M |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.52 | N/A |
| Revenue | ★ $1,450,448,000.00 | $22,286,000.00 |
| Revenue This Year | $8.30 | $342.39 |
| Revenue Next Year | $7.17 | $170.71 |
| P/E Ratio | $68.13 | ★ N/A |
| Revenue Growth | ★ 25.02 | N/A |
| 52 Week Low | $89.25 | $60.36 |
| 52 Week High | $222.53 | $115.14 |
Technical Indicators
Market Signals| Indicator | EPAM | ACLX |
|---|---|---|
| Relative Strength Index (RSI) | 41.11 | 79.86 |
| Support Level | $89.25 | $63.46 |
| Resistance Level | $165.81 | N/A |
| Average True Range (ATR) | 5.55 | 0.11 |
| MACD | 1.53 | -0.62 |
| Stochastic Oscillator | 62.66 | 84.28 |
Price Performance
Historical ComparisonAbout EPAM EPAM Systems Inc.
EPAM Systems is a global IT services firm with a focus on platform engineering, software development, and consulting services. The company used to host large engineer bases in Ukraine, Belarus, and Russia, but it now delivers from various locations across different continents. EPAM's largest market is North America, which represents approximately 60% of revenue.
About ACLX Arcellx Inc.
Arcellx Inc a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases. Its pipeline includes Multiple Myeloma, Acute Myeloid Leukemia, Non-Oncology, and Solid Tumors.